| Dr Barbara J Merriman, DO | |
|
2929 5th St, Rapid City, SD 57701-7363 | |
| (605) 755-1000 | |
| Not Available |
| Full Name | Dr Barbara J Merriman |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 11 Years |
| Location | 2929 5th St, Rapid City, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295173656 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 10495 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Fairview Hospital | Cleveland, OH | Hospital |
| Monument Health Sturgis Hospital | Sturgis, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.
In a recent study, screening rates for hepatitis C virus (HCV) infection among baby boomers increased fivefold in the year following implementation of an electronic health record (EHR)-based prompt for primary care physicians.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.
› Verified 3 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.
In a recent study, screening rates for hepatitis C virus (HCV) infection among baby boomers increased fivefold in the year following implementation of an electronic health record (EHR)-based prompt for primary care physicians.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barbara J Merriman, DO 2929 5th St, Rapid City, SD 57701-7363 Ph: (605) 755-1000 | Dr Barbara J Merriman, DO 2929 5th St, Rapid City, SD 57701-7363 Ph: (605) 755-1000 |
News Archive
NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.
Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.
In a recent study, screening rates for hepatitis C virus (HCV) infection among baby boomers increased fivefold in the year following implementation of an electronic health record (EHR)-based prompt for primary care physicians.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.
› Verified 3 days ago
Steven K Hata, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2929 5th Street, 240, Rapid City, SD 57701 Phone: 605-341-3770 Fax: 605-341-8692 | |
Dr. Douglas Thorburn Brown, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2929 5th Street, 240, Rapid City, SD 57701 Phone: 605-341-3770 Fax: 605-341-8692 | |
Kirsten A Butz, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 915 Mt View Rd, Rapid City, SD 57702 Phone: 605-755-7300 Fax: 605-755-0707 | |
Dr. Terry R Hicks, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 350 Elk St, Rapid City, SD 57701 Phone: 605-343-7262 Fax: 605-343-7293 | |
Dr. Ryan Gianatasio, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 677 Cathedral Dr, Rapid City, SD 57701 Phone: 605-755-4150 | |
Dr. Mark Thomas Garry, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10 Van Buren St, Rapid City, SD 57701 Phone: 605-721-8939 | |
Heather G Cwach, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2929 5th Street, 240, Rapid City, SD 57701 Phone: 605-341-3770 Fax: 605-341-8692 |